Press coverage about Recro Pharma (NASDAQ:REPH) has been trending somewhat positive recently, according to Accern. The research group ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Recro Pharma earned a news impact score of 0.03 on Accern’s scale. Accern also gave media stories about the specialty pharmaceutical company an impact score of 46.355994444805 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:
- Recro Pharma, Inc. (REPH) Given Consensus Rating of “Buy” by Analysts (americanbankingnews.com)
- Recro Pharma, Inc. (REPH) Lowered to “Sell” at Zacks Investment Research (americanbankingnews.com)
- Recro Pharma (REPH) Reports Phase III IV Meloxicam Clinical … – StreetInsider.com (streetinsider.com)
- Recro Pharma Presents Phase III IV Meloxicam Clinical Efficacy Data in Patients Following Abdominoplasty at the 2017 American Society of Plastic Surgeons Annual Meeting (finance.yahoo.com)
- Stock Buy Signal: Recro Pharma, Inc. (REPH) – Street Observer (press release) (streetobserver.com)
Shares of Recro Pharma (NASDAQ REPH) traded down 2.79% during mid-day trading on Friday, hitting $8.36. The stock had a trading volume of 61,963 shares. Recro Pharma has a 52-week low of $5.81 and a 52-week high of $10.17. The company’s 50 day moving average is $8.24 and its 200-day moving average is $7.74. The stock’s market cap is $159.33 million.
Recro Pharma (NASDAQ:REPH) last issued its quarterly earnings data on Thursday, August 10th. The specialty pharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.54) by $0.06. The company had revenue of $16.93 million for the quarter, compared to analyst estimates of $14.90 million. Recro Pharma had a negative net margin of 46.75% and a negative return on equity of 56.04%. On average, equities research analysts anticipate that Recro Pharma will post ($2.35) earnings per share for the current fiscal year.
Several analysts have weighed in on the company. Zacks Investment Research cut Recro Pharma from a “hold” rating to a “sell” rating in a research report on Wednesday. Piper Jaffray Companies set a $11.00 price objective on Recro Pharma and gave the company a “buy” rating in a research report on Tuesday, July 25th. Finally, Roth Capital set a $20.00 price target on Recro Pharma and gave the stock a “buy” rating in a research report on Monday, July 31st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. Recro Pharma presently has an average rating of “Buy” and an average target price of $12.63.
TRADEMARK VIOLATION WARNING: This article was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://sportsperspectives.com/2017/10/13/recro-pharma-reph-receiving-somewhat-positive-media-coverage-analysis-shows.html.
Recro Pharma Company Profile
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
Receive News & Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.